Incyte Corporation (INCY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $24.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Incyte Corporation (INCY) Earnings: Report Dates and Results
Incyte (INCY) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Incyte reported EPS of -$3.79, above the -$4.27 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INCY has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 12.8% above the $1.80 reported for the quarter ended Dec 31, 2025.
INCY Earnings Call
The latest INCY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, INCY beat 21 and missed 19. Revenue for the quarter ended Sep 30, 2026 was $1.56B, up 13.9% from $1.37B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$3.79 | -$4.27 | -$4.46 - -$2.85 | +11.24% | Beat | -267.7% | 16 | 0 up, 2 down | Oct 29, 2026 | $1.56B |
| Jun 30, 2026 | $2.80 | $1.76 | $1.63 - $2.85 | +59.09% | Beat | +78.3% | 19 | 2 up, 2 down | Jul 28, 2026 | $1.67B |
| Mar 31, 2026 | $1.81 | $1.34 | $0.90 - $1.68 | +35.07% | Beat | +56.0% | 17 | 2 up, 6 down | Apr 28, 2026 | $1.27B |
| Dec 31, 2025 | $1.80 | $1.92 | $1.71 - $2.18 | -6.25% | Miss | +25.9% | 15 | 6 up, 0 down | Feb 10, 2026 | $1.51B |
| Sep 30, 2025 | $2.26 | $1.64 | $1.29 - $1.85 | +37.80% | Beat | +111.2% | 16 | 4 up, 2 down | Oct 28, 2025 | $1.37B |
| Jun 30, 2025 | $1.57 | $1.47 | $1.29 - $2.36 | +6.80% | Beat | N/A | 15 | 3 up, 2 down | Jul 29, 2025 | $1.22B |
| Mar 31, 2025 | $1.16 | $1.03 | $0.76 - $1.35 | +12.62% | Beat | +81.2% | 14 | N/A | Apr 29, 2025 | $1.05B |
| Dec 31, 2024 | $1.43 | $1.55 | $1.29 - $1.94 | -7.74% | Miss | +34.9% | 14 | 7 up, 3 down | Feb 10, 2025 | $1.18B |
| Sep 30, 2024 | $1.07 | $1.09 | $0.72 - $1.84 | -1.83% | Miss | -2.7% | 15 | 2 up, 4 down | Oct 29, 2024 | $1.14B |
| Jun 30, 2024 | -$1.82 | $1.11 | N/A | -263.96% | Miss | -283.8% | 2 | 6 up, 2 down | Jul 30, 2024 | $1.04B |
| Mar 31, 2024 | $0.64 | $0.83 | $0.55 - $1.06 | -22.89% | Miss | +73.0% | 12 | 4 up, 1 down | Apr 30, 2024 | $880.89M |
| Dec 31, 2023 | $1.06 | $1.15 | $0.97 - $1.34 | -7.83% | Miss | +71.0% | 15 | 3 up, 0 down | Feb 13, 2024 | $1.01B |
| Sep 30, 2023 | $1.10 | $1.07 | $0.63 - $1.21 | +2.80% | Beat | +83.3% | 12 | 2 up, 1 down | Oct 31, 2023 | $919.02M |
| Jun 30, 2023 | $0.99 | $0.87 | $0.58 - $1.23 | +13.79% | Beat | -2.0% | 12 | 4 up, 2 down | Aug 1, 2023 | $954.61M |
| Mar 31, 2023 | $0.37 | $0.74 | $0.46 - $1.00 | -50.00% | Miss | -32.7% | 13 | 4 up, 0 down | May 2, 2023 | $808.67M |
| Dec 31, 2022 | $0.62 | $0.57 | $0.39 - $0.76 | +8.77% | Beat | +520.0% | 13 | 1 up, 2 down | Feb 7, 2023 | $926.70M |
| Sep 30, 2022 | $0.60 | $0.71 | $0.53 - $0.87 | -15.49% | Miss | -49.2% | 12 | 2 up, 6 down | Nov 1, 2022 | $823.30M |
| Jun 30, 2022 | $1.01 | $0.75 | $0.36 - $0.96 | +34.67% | Beat | +26.2% | 12 | 4 up, 0 down | Aug 2, 2022 | $911.40M |
| Mar 31, 2022 | $0.55 | $0.69 | $0.39 - $0.95 | -20.29% | Miss | -17.9% | 9 | 1 up, 2 down | May 3, 2022 | $733.24M |
| Dec 31, 2021 | $0.10 | $0.87 | $0.67 - $1.09 | -88.51% | Miss | -89.2% | 11 | 3 up, 0 down | Feb 8, 2022 | $862.85M |
| Sep 30, 2021 | $1.18 | $0.76 | $0.51 - $0.88 | +55.26% | Beat | +413.0% | 10 | 0 up, 0 down | Nov 2, 2021 | $812.99M |
| Jun 30, 2021 | $0.80 | $0.74 | $0.61 - $0.88 | +8.11% | Beat | -35.5% | 10 | N/A | Aug 3, 2021 | $705.71M |
| Mar 31, 2021 | $0.67 | $0.64 | $0.53 - $0.79 | +4.69% | Beat | N/A | 10 | N/A | May 4, 2021 | $604.72M |
| Dec 31, 2020 | $0.93 | $0.77 | $0.20 - $1.04 | +20.78% | Beat | +43.1% | 12 | N/A | Feb 9, 2021 | $789.51M |
| Sep 30, 2020 | $0.23 | $0.76 | $0.64 - $0.89 | -69.74% | Miss | -72.0% | 12 | N/A | Nov 5, 2020 | $620.64M |
| Jun 30, 2020 | $1.24 | $0.86 | $0.55 - $1.29 | +44.19% | Beat | +65.3% | 12 | N/A | Aug 4, 2020 | $688.04M |
| Mar 31, 2020 | -$2.86 | -$2.80 | N/A | -2.14% | Miss | -561.3% | 9 | N/A | May 5, 2020 | $568.51M |
| Dec 31, 2019 | $0.65 | $0.58 | $0.31 - $0.88 | +12.07% | Beat | +62.5% | 12 | N/A | Feb 13, 2020 | $579.39M |
| Sep 30, 2019 | $0.82 | $0.64 | $0.50 - $0.84 | +28.13% | Beat | +115.8% | 14 | N/A | Oct 29, 2019 | $551.58M |
| Jun 30, 2019 | $0.75 | $0.50 | $0.32 - $0.65 | +50.00% | Beat | +188.5% | 12 | N/A | Jul 30, 2019 | $529.93M |
| Mar 31, 2019 | $0.62 | $0.41 | $0.24 - $0.60 | +51.22% | Beat | N/A | 13 | N/A | Apr 30, 2019 | $497.86M |
| Dec 31, 2018 | $0.40 | $0.46 | $0.20 - $0.61 | -13.04% | Miss | N/A | 13 | N/A | Feb 14, 2019 | $528.40M |
| Sep 30, 2018 | $0.38 | $0.41 | $0.33 - $0.53 | -7.32% | Miss | +123.5% | 14 | N/A | Oct 30, 2018 | $449.68M |
| Jun 30, 2018 | $0.26 | $0.22 | $0.19 - $0.65 | +18.18% | Beat | N/A | 11 | N/A | Jul 31, 2018 | $521.52M |
| Mar 31, 2018 | -$0.01 | $0.12 | -$0.30 - $0.32 | -108.33% | Miss | N/A | 11 | N/A | May 1, 2018 | $382.28M |
| Dec 31, 2017 | -$0.71 | -$0.45 | -$0.64 - $0.09 | -57.78% | Miss | -1520.0% | 18 | N/A | Feb 15, 2018 | $444.16M |
| Sep 30, 2017 | $0.17 | $0.06 | -$0.01 - $0.17 | +183.33% | Beat | -10.5% | 16 | N/A | Oct 31, 2017 | $381.53M |
| Jun 30, 2017 | -$0.06 | -$0.04 | -$0.16 - $0.18 | -50.00% | Miss | -133.3% | 13 | N/A | Aug 1, 2017 | $326.44M |
| Mar 31, 2017 | -$0.96 | -$0.88 | N/A | -9.09% | Miss | -900.0% | N/A | N/A | May 4, 2017 | $384.08M |
| Dec 31, 2016 | $0.05 | $0.14 | N/A | -64.29% | Miss | -82.8% | N/A | N/A | Feb 14, 2017 | $326.50M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.79, up 414.4% from the year before. It was $0.54 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.79 | +414.4% |
| Dec 31, 2024 | $1.32 | -62.5% |
| Dec 31, 2023 | $3.52 | +26.6% |
| Dec 31, 2022 | $2.78 | N/A |
| Dec 31, 2021 | $2.75 | N/A |
| Dec 31, 2020 | -$0.46 | -116.2% |
| Dec 31, 2019 | $2.84 | +175.7% |
| Dec 31, 2018 | $1.03 | N/A |
| Dec 31, 2017 | -$1.56 | -388.9% |
| Dec 31, 2016 | $0.54 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 23 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,446 | 23 | |
| 2026Q2 | Jun 30, 2026 | 8,401 | 20 | |
| 2026Q1 | Mar 31, 2026 | 7,542 | 20 | |
| 2025Q4 | Dec 31, 2025 | 9,690 | 22 | |
| 2025Q3 | Sep 30, 2025 | 8,878 | 20 | |
| 2025Q2 | Jun 30, 2025 | 9,448 | 20 | |
| 2025Q1 | Mar 31, 2025 | 9,040 | 26 | |
| 2024Q4 | Dec 31, 2024 | 8,444 | 22 |
2026Q3 Earnings Call
Opening remarks
Alexis Smith Vice President, Head of Investor Relations Thank you. Good morning, and welcome to Incyte's third quarter 2026 earnings conference call. Before we begin, I encourage everyone to go to the investor section of our website to find the press release, related financial tables, and slides that follow today's discussion. On today's call, I am joined by Bill, Pablo, and Suky, who will deliver our prepared remarks. Steven, Dave, and Mohamed will also be available for Q&A. I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. I will now hand the call over to Bill.
Bill Meury CEO Thanks, Alexis, and good morning, everyone. As we look at the first nine months of the year, we have made meaningful progress against the strategy we laid out for Incyte. That strategy has two fundamental components: scaling the core business beyond Jakafi and advancing our late-stage pipeline to drive the next phase of growth. The core business is the foundation that gives us the scale to navigate the 2029 transition and fund R&D. Layering the pipeline on top of that gives us the opportunity to build a significantly larger company over the next decade. We now have several compounds in Phase III development, including a mutant CALR antibody for MPNs, a Protein S modulator for von Willebrand disease, a G12D inhibitor for pancreatic cancer, a TGFβ×PD-1 bispecific antibody in colorectal cancer, a CDK2 inhibitor for ovarian cancer, and a JAK inhibitor currently under regulatory review in HS. We have increasing confidence in the biology behind these programs and believe we have taken meaningful risks out of them as they have advanced. That does not mean the risk is zero, but increasingly the risk we are managing is execution risk: running high-quality Phase III programs, enrolling them on time, and achieving the regulatory milestones in front of us. Those are things we directly control, and that is our focus today. We are fully funding and resourcing these opportunities, leaving nothing to chance. If we deliver against them, we believe the value creation potential is substantial, and that is how we should ultimately be judged. Now we will frame the quarter around three themes. First, key business performance. Every product grew year-over-year. Jakafi had another strong quarter with growth across all indications, and sales from our core business, excluding Jakafi, increased 37% from the prior year. Second, we achieved important regulatory milestones, including the approval and launch of OPZELURA for moderate AD in the EU in the third quarter.
Frequently Asked Questions About INCY
When is Incyte's next earnings date?
Incyte's next earnings report is expected for Feb 8, 2027.
Did INCY beat earnings estimates last quarter?
Yes. Incyte reported EPS of -$3.79 for the quarter ended Sep 30, 2026, above the -$4.27 estimate, a 11.24% surprise.
What EPS do analysts expect from INCY next quarter?
The consensus EPS estimate for Incyte for the quarter ending Dec 31, 2026 is $2.03 from 26 analysts, with estimates from $1.56 to $3.23.
How often does INCY beat earnings estimates?
Incyte beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +18.58%.
INCY pages: Overview, Earnings, Forecast, Financials, Valuation